In recent trading session, Ginkgo Bioworks Holdings Inc (NYSE:DNA) saw 0.47 million shares changing hands at last check today with its beta currently measuring 1.29. Company’s recent per share price level of $7.14 trading at $0.68 or 10.53% at last check today assigns it a market valuation of $414.36M. That most recent trading price of DNA’s stock is at a discount of -572.27% from its 52-week high price of $48.00 and is indicating a premium of 26.33% from its 52-week low price of $5.26. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.61 million shares which gives us an average trading volume of 1.72 million if we extend that period to 3-months.

For Ginkgo Bioworks Holdings Inc (DNA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.83. Splitting up the data highlights that, out of 5 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.

Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information

Upright in the green today for gaining 10.53%, in the last five days DNA remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $7.14 price level, adding 3.77% to its value on the day. Ginkgo Bioworks Holdings Inc’s shares saw a change of -27.29% in year-to-date performance and have moved -5.31% in past 5-day. Ginkgo Bioworks Holdings Inc (NYSE:DNA) showed a performance of -42.05% in past 30-days. Number of shares sold short was 9.06 million shares which calculate 4.28 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 6.5 to the stock, which implies a fall of -9.85% to its recent value today. Analysts have been projecting 4.35 as a low price target for the stock while placing it at a high target of 12. It follows that stock’s current price would jump 39.08% in reaching the projected high whereas dropping to the targeted low would mean a gain of 39.08% for stock’s current value.

Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts

This year revenue growth is estimated to fall -23.22% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 39.34M for the same. And 5 analysts are in estimates of company making revenue of 43.62M in the next quarter. Company posted 37.94M and 56.21M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -27.97% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 49.93% while estimates for its earnings growth in next 5 years are of 48.92%.

Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders

Insiders are in possession of 6.57% of company’s total shares while institution are holding 79.85 percent of that, with stock having share float percentage of 85.46%. Investors also watch the number of corporate investors in a company very closely, which is 79.85% institutions for Ginkgo Bioworks Holdings Inc that are currently holding shares of the company. VIKING GLOBAL INVESTORS LP is the top institutional holder at DNA for having 143.09 million shares of worth $47.83 million. And as of 2024-06-30, it was holding 6.9686 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 138.96 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.9327 of outstanding shares, having a total worth of $46.46 million.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 1.17 shares of worth $8.24 million or 2.55% of the total outstanding shares. The later fund manager was in possession of 640.67 shares on Dec 31, 2024, making its stake of worth around $4.52 million in the company or a holder of 1.40% of company’s stock.